" class="no-js "lang="en-US"> Todd Druley - Medtech Alert
Saturday, September 13, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Todd Druley

Todd Druley

About Todd Druley

Todd Druley, MD, PhD established his career as a board-certified pediatric oncologist and tenured physician-scientist in molecular genomics at Washington University School of Medicine and St. Louis Children’s Hospital. Todd’s research program focused on improving molecular diagnostics for a variety of cancers, but specifically myeloid leukemia. He has published over 60 peer reviewed manuscripts, patented error-corrected NGS methods to improve AML MRD detection by next-generation sequencing and built clinical programs based on genetic predisposition to cancer. Prior to joining Mission Bio, he served as CMO of ArcherDX and ANGLE Biosciences since 2019.

I am a physician-scientist trained in pediatric hematology and oncology working to bring advanced genomic diagnostics to patient care through the biotech industry and academia. My expertise lies in translational genomic and computational tools to improve clinical diagnostics and apply these tools to disease-specific questions in cancer.

Specialties: Pediatric hematology, pediatric oncology, genomics, cancer genetics, rare genetic variation

Related Story

Diseases

 IDIBAPS Researchers Discover Genetic Drivers of Clonal Evolution in Leukemia Using Single-Cell DNA Sequencing from Mission Bio | Pharmtech Focus

IDIBAPS Researchers Discover Genetic Drivers of Clonal Evolution in Leukemia Using Single-Cell DNA Sequencing from Mission Bio

August 12 2022

Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced new findings from […]